Efficacy and Safety Study of Two Fixed-Dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate, and Placebo All Administered Twice Daily (BID) to Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

Efficacy and Safety Study of Two Fixed-Dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate, and Placebo All Administered Twice Daily (BID) to Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Aclidinium bromide; Aclidinium bromide/formoterol; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 04 Oct 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 03 Feb 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 03 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top